Scribd Logo
Upload

Welcome to Scribd!

  • Financial Projection Charts

    Uploaded by

    Wenxuan Zheng
    20 views1 page
    The document shows a biotech company's revenues, operating expenses, cash inflows, and end of year cash from 2002 to 2005. Revenues grew steadily each year, driven mainly by contract revenue and milestones/royalties. Operating expenses also increased annually with the largest portions going to compensation, facilities/equipment, and professional services. Cash inflows came primarily from stock sales, loans, and strategic partner advances. End of year cash balances rose over the period from $10 million to $30 million.

    Original Description:

    Copyright

    © Attribution Non-Commercial (BY-NC)

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    The document shows a biotech company's revenues, operating expenses, cash inflows, and end of year cash from 2002 to 2005. Revenues grew steadily each year, driven mainly by contract revenue and milestones/royalties. Operating expenses also increased annually with the largest portions going to compensation, facilities/equipment, and professional services. Cash inflows came primarily from stock sales, loans, and strategic partner advances. End of year cash balances rose over the period from $10 million to $30 million.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    Download as pdf or txt
    20 views1 page

    Financial Projection Charts

    Uploaded by

    Wenxuan Zheng
    The document shows a biotech company's revenues, operating expenses, cash inflows, and end of year cash from 2002 to 2005. Revenues grew steadily each year, driven mainly by contract revenue and milestones/royalties. Operating expenses also increased annually with the largest portions going to compensation, facilities/equipment, and professional services. Cash inflows came primarily from stock sales, loans, and strategic partner advances. End of year cash balances rose over the period from $10 million to $30 million.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    Download as pdf or txt
    of 1

    Revenues Operating Expenses

    $20,000,000
    $4,000,000

    $3,500,000
    $15,000,000
    $3,000,000
    Milestones &
    Royalties
    $2,500,000
    Contract $10,000,000
    Revenue
    $2,000,000 Other Revenues

    $1,500,000 $5,000,000

    $1,000,000

    $500,000 $-
    2002 2003 2004 2005
    $- Compensation Facilities & Equipment Professional Services

    2002 2003 2004 2005 Science Services Manufacturing Product Testing


    Preclinical/Clinicals Other Expenses Depreciation

    End of Year Cash Cash Inflows

    $35,000,000
    $35,000,000
    Sale of Stock, net
    Loans
    $30,000,000
    $30,000,000 Strategic Partner Advances
    Other Revenues
    Interest & other
    $25,000,000 $25,000,000

    $20,000,000 $20,000,000

    $15,000,000 $15,000,000

    $10,000,000 $10,000,000

    $5,000,000 $5,000,000

    $-
    $-
    2002 2003 2004 2005
    2002 2003 2004 2005

    You might also like